Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Top Cited Papers
- 15 August 2008
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 321 (5891), 974-977
- https://doi.org/10.1126/science.1158545
Abstract
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non–Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell–engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.Keywords
This publication has 26 references indexed in Scilit:
- Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancerImmunology Letters, 2008
- Update on anti-CTLA-4 antibodies in clinical trials.Expert Opinion on Biological Therapy, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody constructCancer Immunology, Immunotherapy, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic MelanomaJournal of Clinical Oncology, 2005
- Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody constructInternational Journal of Cancer, 2005
- High Frequency of Functionally Active Melan-A–Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient MelanomaCancer Research, 2004
- A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.Proceedings of the National Academy of Sciences, 1995